对α-defensins作为慢性阻塞性肺病严重性标记物的评估
Kritika Kumar1, Komaldeep Kaur1, Shivani Jaswal2
1Department of Pulmonary Critical Care and Sleep Medicine, Government Medical College and Hospital, Chandigarh, India.
Lung India : official organ of Indian Chest Society
|July 2, 2024
概括
唾液中的α-defensins显示出诊断慢性阻塞性肺病 (COPD) 和预测急性恶化的潜力. 升高的水平表明疾病的严重程度,与肺功能减弱相关.
科学领域:
- 免疫学 免疫学 免疫学
- 肺部病理学 肺部病理学
- 生物标志物发现发现
背景情况:
- 防御素是关键的先天免疫分子.
- 阿尔法-防御素在慢性阻塞性肺病 (COPD) 中起作用.
- 在血清和唾液中定量α-defensins是COPD研究的关键.
研究的目的:
- 研究alpha-defensins在COPD患者中的作用.
- 评估alpha-defensins作为COPD的诊断和监测生物标志物.
- 评估唾液α-defensin在COPD诊断中的实用性.
主要方法:
- 180名患者被分为四组.
- 血清和唾液中的α-defensin水平被量化.
- 评估了唾液α-defensin的诊断准确性.
主要成果:
- 液α-defensin水平在不同组之间有显著差异 (P < 0.001).
- 在COPD急性恶化 (AECOPD) 中观察到最高水平.
- 唾液α-defensins与FEV1负相关 (rho = -0.31,P < 0.001). 唾液α-defensins与FEV1负相关 (rho = -0.31,P < 0.001). 唾液α-defensins与FEV1负相关 (rho = -0.31,P < 0.001). 唾液α-defensins与FEV1负相关 (rho = -0.31,P < 0.001). 唾液α-defensins与FEV1负相关 (rho = -0.31,P < 0.001). 唾液α-defensins与FEV1负相关 (rho = -0.31,P < 0.001).
结论:
- 唾液α-defensins显示承诺作为COPD急性恶化预测标记.
- 在COPD患者中,α-defensins可以表明疾病的严重程度.
- 唾液α-defensins可能成为COPD管理中的一个有价值的生物标志物.
相关概念视频
01:27Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
2.5K
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
Medical History
2.5K
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.8K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.8K
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
2.8K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
2.8K
01:22Chronic Obstructive Pulmonary Disease
1.2K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
1.2K
01:30Pneumonia III: Complications and Assessment
198
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
198
01:26COPD: Management Using Bronchodilators and Corticosteroids
194
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
194